Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature

Respirology Case Reports

Mihoko Imaji¹  Mai Kato¹  Daichi Fujimoto¹  Nobuyuki Yamamoto¹  Masanori Tanaka¹  Katsuyuki Furuta¹ 

[1] Internal Medicine III Wakayama Medical University Wakayama Japan;

关键词: Atezolizumab;    carboplatin;    etoposide;    extensive‐stage small cell lung cancer;    haemodialysis;   

DOI  :  10.1002/rcr2.741

来源: DOAJ

【 摘 要 】

Abstract Little is known about the safety of chemotherapy plus atezolizumab for patients with extensive‐stage small cell lung cancer (ES‐SCLC) undergoing haemodialysis (HD). An 80‐year‐old male received carboplatin [area under the concentration‐time curve (AUC) = 5 on day 1], etoposide (40 mg/m2 on days 1, 2, and 3), and atezolizumab (1200 mg/body on day 1) as the first‐line therapy for ES‐SCLC. He was undergoing HD thrice a week for seven years. HD was provided 16 h after carboplatin administration. During the first cycle, grade 4 neutropenia (neutrophil count: 74/μL) and leukopenia (white blood cell count: 680/μL) occurred. Therefore, chemotherapy was administered with a reduced dose of carboplatin (AUC = 4) and etoposide (30 mg/m2) from the second to fourth cycles. After four cycles, no severe non‐haematological adverse events occurred, showing a remarkable response. We conclude that the carboplatin, etoposide, and atezolizumab combination can be safely administered to cancer patients undergoing HD.

【 授权许可】

Unknown